中国儿童系统性红斑狼疮诊疗指南

标题: 中国儿童系统性红斑狼疮诊疗指南
title: Chinese guidelines for the diagnosis and treatment of childhood-onset systemic lupus erythematosus
版本: 原创版
version: Original
分类: 标准指南
classification: Standard guideline
领域: 诊疗
field: Diagnosis and Management
国家和地区: 中国
Country and region: China
指南使用者: 指南适用于对目标人群提供卫生保健服务的医疗机构以及卫生管理部门,主要使用人群为风湿免疫科、儿科及检验科相关临床医师。
Guide users: The target implementation agencies include medical institutions and health authorities that provide health care services to the target population. The target end users of this guideline are medical workers in rheumatology, pediatric and laboratory.
证据分级方法:
Evidence grading method: The GRADE approach will be used to assess the quality of evidence for each clinical question. According to the GRADE approach, the quality of evidence can be classified as high, moderate, low, and very low and the results will be drafted and presented in the form of evidence summary table. Randomized controlled trials are regarded as high-quality evidence while observational studies as low-quality evidence. Then initial quality can be downgraded for five reasons (study limitations, consistency of effect, imprecision, indirectness, and publication bias) and upgraded for three reasons (large magnitude of effect, dose-response relation and plausible confounders or biases).
制定单位: 中华医学会儿科学分会免疫学组和《中华儿科杂志》编辑部
Formulating unit: Group of Immunology of Society of Pediatrics from Chinese Medical Association and editorial office of The Chinese Journal of Pediatrics
注册时间: 2020-07-31
Registration time:
注册编号: IPGRP-2020CN105
Registration number:
指南制订的目的: 指南工作组将严格遵照国际组织关于指南制订的标准和流程,优选儿童系统性红斑狼疮临床实践中存在的具体问题,系统地检索、评价及制作证据体,并考虑患者的偏好与价值观,结合我国临床实际和多学科专家的经验,旨在制订出一部立足于患者、以临床问题为导向、循证医学为支托的高质量循证指南。该指南的制订将有助于规范我国儿童系统性红斑狼疮的管理,改善患者预后结局,降低医疗成本和经济负担,提高医疗服务整体水平。
Purpose of the guideline: To develop a patient-based, clinical problem-oriented, evidence-based and high-quality guideline, the Guideline Working Group will strictly follow the standards and procedures of international organizations, select optimal specific problems in clinical practice of cSLE, systematically search, assess and syntheses evidence, consider patients’ value and preferences by combing with the clinical practice of China and experience from multidisciplinary experts. The development of this guideline will help to standardize the management of cSLE in China, improve the prognosis of patients, reduce medical costs and economic burden, and improve the overall level of medical services.